Concurrent Treatment With Rituximab and Plasma Exchange for Rapidly Progressive Interstitial Lung Disease Complicating Anti-MDA5 Antibody-Positive Juvenile Dermatomyositis

J Clin Rheumatol. 2021 Dec 1;27(8S):S798-S799. doi: 10.1097/RHU.0000000000001460.

Authors

Masaki Shimizu¹, Natsumi Inoue¹, Yoshikatsu Takeda¹, Kensuke Kidouchi¹, Naohisa Fujita¹, Toshihiro Fujiki¹, Asami Takasaki², Yuichi Adachi², Taizo Wada¹

Affiliations

¹ From the Department of Pediatrics, School of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa.
² Department of Pediatrics, Graduate School of Medicine and Pharmaceutical Science, University of Toyama, Toyama, Japan.

PMID: 35073639
DOI: 10.1097/RHU.0000000000001460

No abstract available

MeSH terms

Autoantibodies
Dermatomyositis* / complications
Dermatomyositis* / diagnosis
Dermatomyositis* / drug therapy
Disease Progression
Humans
Interferon-Induced Helicase, IFIH1
Lung Diseases, Interstitial* / diagnosis
Lung Diseases, Interstitial* / etiology
Lung Diseases, Interstitial* / therapy
Plasma Exchange
Rituximab

Substances

Autoantibodies
Rituximab
Interferon-Induced Helicase, IFIH1